Share
27,097 Posts.
lightbulb Created with Sketch. 1752
clock Created with Sketch.
03/07/20
00:44
Share
Originally posted by Runandjump27
↑
from my own research both companies have pivoted too many times...
both now claim to be on the cusp of commercialisation!
as said I just want to see management forecasts and key assumptions it is now a revenue race I am both to get there I just want RAP to drop back to my expected entry price of 10-12 cents... that will push RAP market cap back closer to RSH. IMO RAP still has revenue priced into its share price but has not given guidance to justify this. At this point in time I feel IMO that RSH because of its history as you have correctly pointed out does not have any revenue priced into share price hence why I jumped in today. The stupid thing with all these arguments is the market is more than big enough for multiple respiratory unicorns on the ASX! You spoke about putting $100k on RSH tread so assume there is a 10x from here for us all then as Eddie says who wants to be a millionaire WINS!!
DYOR IMO
Expand
RAP has 3 products compared to RSH's 1 product and that 1 product doesn't provide for chronic COPD patient so RAP's MC isn't high compared to RSH...it's that simple really.
Last edited by
AlCp :
03/07/20